Vyzulta (latanoprostene bunod)
Status:
Concluded with an LOI
Manufacturer:
Bausch Health, Canada Inc.
Indication:
Open-angle Glaucoma
Last updated November 20, 2019
Status:
Concluded with an LOI
Manufacturer:
AstraZeneca Canada Inc.
Indication:
Non-Small Cell Lung Cancer (First-line, locally advanced or metastatic)
Last updated November 19, 2019
Status:
Concluded with an LOI
Manufacturer:
Bayer Inc.
Indication:
Prevention of stroke and cardiovascular events in coronary and peripheral artery disease.
Last updated November 15, 2019
Status:
Concluded with an LOI
Manufacturer:
Teva Canada Ltd.
Indication:
Early breast cancer, Metastatic breast cancer, Metastatic gastric cancer
Last updated November 13, 2019
Status:
Concluded with an LOI
Manufacturer:
Eisai Limited
Indication:
Hepatocellular Carcinoma (HCC) in adults after prior therapy
Last updated November 8, 2019
Status:
Concluded with an LOI
Manufacturer:
Ipsen Biopharmaceuticals Canada, Inc.
Indication:
Renal Cell Carcinoma
Last updated November 5, 2019
Iluvien (fluocinolone acetonide)
Status:
Negotiations were not pursued
Manufacturer:
Knight Therapeutics Inc.
Indication:
Diabetic Macular Edema
Last updated November 1, 2019
Status:
Concluded without agreement
Manufacturer:
Hoffmann-La Roche Ltd.
Indication:
Breast Cancer
Last updated October 29, 2019
Venclexta/rituximab (venetoclax/rituximab)
Status:
Concluded with an LOI
Manufacturer:
AbbVie Corporation
Indication:
In combination with rituximab (V+R) is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy
Last updated October 28, 2019
Lonsurf (trifluridine/tipiracil)
Status:
Negotiations were not pursued
Manufacturer:
Taiho Pharma Canada Inc.
Indication:
Metastatic Colorectal Cancer
Last updated October 18, 2019